Short Interest in Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Decreases By 29.6%

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 21,900 shares, a decrease of 29.6% from the March 15th total of 31,100 shares. Based on an average daily volume of 25,800 shares, the days-to-cover ratio is presently 0.8 days.

Medexus Pharmaceuticals Stock Up 5.0 %

Shares of MEDXF traded up $0.09 during trading hours on Friday, hitting $1.78. 8,875 shares of the stock were exchanged, compared to its average volume of 31,371. Medexus Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $3.88. The stock’s 50-day moving average price is $1.83 and its two-hundred day moving average price is $2.03.

Analyst Upgrades and Downgrades

Separately, Raymond James reaffirmed a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research note on Monday, February 3rd.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.